Author(s): Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, et al.
Aims: To evaluate the cardiovascular risk associated with the presence of the Metabolic Syndrome in Type 2 diabetic subjects.
Methods: Subjects with the Metabolic Syndrome, defined by WHO criteria, were identified in a large sample of non-insulin-treated Type 2 diabetic patients examined within the Verona Diabetes Complications Study (n = 946). At baseline and after a mean of 4.5 years follow-up, cardiovascular disease (CVD) was assessed by medical history, physical examination, electrocardiogram (ECG) and echo-duplex of carotid and lower limb arteries. Death certificates and medical records of subjects who died during the follow-up were scrutinized in order to identify CVD deaths. In statistical analyses, CVD was considered as an aggregate end-point, including fatal and non-fatal coronary, cerebrovascular and peripheral vascular disease as well as ischaemic ECG abnormalities and vascular lesions at the echo-duplex.
Results: The proportion of subjects with the Metabolic Syndrome was very high (92.3%). At the baseline, 31.7% of subjects were coded positive for CVD, which was more prevalent in subjects with the Metabolic Syndrome (32.9 vs. 17.8%, P = 0.005). Among subjects free of CVD at the baseline (n = 559), CVD events during the follow-up were significantly increased in patients with the Metabolic Syndrome as compared with those without it (19.9% vs. 3.9%, P < 0.001). Multiple logistic regression analysis showed that, along with sex, age, smoking and HbA1c, the presence of the Metabolic Syndrome independently predicted prevalent (OR 2.01, P = 0.045) and incident CVD (OR 4.89, P = 0.031).
Conclusions: In Type 2 diabetes, the presence of the Metabolic Syndrome is associated with an almost 5-fold increase in CVD risk.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/14706054
Author(s): Selby JV, Ray GT, Zhang D, Colby CJ
Author(s): Sidorov J, Shull R, Tomcavage J, Girolami S, Lawton N, et al.
Author(s): Cutajar J
Author(s): Costa J, Borges M, David C, Vaz Carneiro A
Author(s): IDF Clinical Guidelines Task Force
Author(s): Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.
Author(s): Selby JV, Karter AJ, Ackerson LM, Ferrara A, Liu J
Author(s): The Mount Hood 4 Modeling Group
Author(s): Clark CM Jr, Snyder JW, Meek RL, Stutz LM, Parkin CG
Author(s): Marcantonio ER, Goldman L, Mangione CM, Ludwig LE, Muraca B, et al.
Author(s): Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al.
Author(s): Carr MC, Brunzell JD
Author(s): van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, et al.
Author(s): Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group
Author(s): Serrano Rios M
Author(s): Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al.
Author(s): Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR
Author(s): Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al.
Author(s): Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, et al.
Author(s): Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R
Author(s): Park JY, Kim HK, Chung YE, Kim SW, Hong SK, et al.
Author(s): Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, et al.
Author(s): Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, et al.
Author(s): Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, et al.
Author(s): Anderson JW, Kendall CW, Jenkins DJ
Author(s): Metascreen Writing Committee, Bonadonna R, Cucinotta D, Fedele D, Riccardi G, et al.
Author(s): Costa LA, Canani LH, Lisbôa HR, Tres GS, Gross GL
Author(s): Handelsman Y, Jellinger PS